Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,019 total articles
Nuvectis Pharma reported its financial results for Q1 2026 and provided updates on its clinical-stage oncology drug NXP900. The Phase 1b trial continues enrolling patients in the US, with preclinical data showing promising synergy of NXP900 combined with RAS inhibitor sotorasib in lung cancer models. The company maintains financial discipline, with…
GD Culture Group Limited announced the receipt of a non-binding proposal from a consortium to acquire all outstanding shares not already owned by the consortium for $10.75 per share in cash, representing a premium of approximately 169% over recent trading prices. The Board plans to evaluate the offer and consider forming a special committee to nego…
Willis Towers Watson (WTW) has completed its acquisition of UK workplace pension and savings provider Cushon, following regulatory approval. This acquisition solidifies WTW's position as the fourth largest master trust provider in the UK defined contribution workplace pensions market, managing over £30 billion in assets for 1.2 million members. The…
Cytokinetics announced that the pivotal Phase 3 ACACIA-HCM trial of aficamten met both of its primary endpoints, showing statistically significant improvements in symptoms and exercise capacity in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The drug demonstrated consistent benefits across key secondary measures with…
Telesat announced its Q1 2026 financial results showing a 25% revenue decline to CAD 87 million largely due to broadcast contract non-renewals in the GEO segment, while investing heavily (CAD 171 million) in its LEO Telesat Lightspeed constellation development targeted for commercial service launch around Q1 2028. The company reported a net loss of…
Rumble Inc. has received the final regulatory approval from the UAE Ministry of Economy for its proposed business combination with Northern Data AG. The transaction has seen significant shareholder participation, with 77% of Northern Data shares secured under tender or support agreements. The combined entity seeks to leverage Northern Data's high-p…
Surgery Partners, Inc. announced its Q1 2026 financial results, showing a 4.5% year-over-year revenue increase to $810.9 million, driven by a 4.4% rise in same-facility revenues. Despite these gains, the company reported a net loss of $35.9 million for the quarter. Adjusted EBITDA was slightly lower at $102.3 million compared to the prior year. The…
BridgeBio Pharma announced that primary results from its Phase 3 CALIBRATE trial of encaleret for autosomal dominant hypocalcemia type 1 (ADH1) will be presented at the 2026 European Congress of Endocrinology. Additional presentations on genetic testing and disease monitoring related to hypoparathyroidism and ADH1 will also be shared, highlighting …
Compass Therapeutics reported positive first quarter 2026 financial results and highlighted significant progress in its oncology pipeline. The Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) combined with paclitaxel showed statistically significant improvements in progression-free survival and overall response rate in biliary tract…
Kura Oncology, a biopharmaceutical company specializing in precision cancer medicines, will report its first quarter 2026 financial results on May 12, 2026. The company will host a webcast and conference call to discuss the results and provide a corporate update. Kura is known for KOMZIFTI, an FDA-approved oral menin inhibitor for certain leukemia …
Intellia Therapeutics, a clinical-stage biopharmaceutical company focused on CRISPR gene editing, will participate in investor fireside chats at three major healthcare conferences in May and June 2026. The events will be webcast live, offering investors insights into the company's mission to develop potentially curative treatments targeting the roo…
Exodus Movement, Inc., a self-custodial payments and cryptocurrency platform, announced it will release its financial results for the first quarter of 2026 on May 12, 2026, after market close. The company will host an earnings webcast that day and provide supplementary materials on its website. Founded in 2015 and headquartered in Omaha, Nebraska, …
Cipher Digital reported significant progress in Q1 2026 with development milestones at its Barber Lake and Black Pearl data center campuses on schedule, signing a third AI data center lease with an investment-grade hyperscale tenant, and securing a $200 million revolving credit facility from leading global financial institutions to support ongoing …
At its General Meetings held on 5 May 2026, ArcelorMittal shareholders approved key corporate actions including a US$0.60 per share dividend distribution, re-election of current directors along with a new director, approval of share cancellation following buybacks, and renewal of board authorization to increase share capital. These approvals suppor…
Sow Good Inc. announced a $20 million non-convertible private placement credit facility with Sagol Advisors to fund its strategic acquisition of the Nachu Graphite Project in Tanzania. This funding supports Sow Good's transition into critical minerals and battery anode materials development, enhancing its position in the battery materials supply ch…
Huntington Ingalls Industries reported first quarter fiscal 2026 revenues of $3.1 billion, up 13.4% year-over-year, driven by growth across its shipbuilding and mission technology segments. Despite higher revenues, operating margins declined slightly, leading to net earnings and diluted EPS of $149 million and $3.79 respectively, unchanged from the…
Fiserv, Inc. reported first quarter 2026 GAAP revenue of $5.03 billion, down 2% year-over-year, with organic revenue down 4%. GAAP EPS declined 29%, and adjusted EPS fell 16%. The company confirmed 2026 organic revenue growth guidance of 1%-3% and adjusted EPS between $8.00 and $8.30. Operating margins declined notably compared to prior year period…
Colliers International Group Inc. announced robust first quarter 2026 financial results, with consolidated revenues rising 15% to $1.31 billion and adjusted EBITDA increasing by 8% to $124.8 million. Adjusted EPS grew 5% to $0.91, reflecting the company's diversified professional services platform's resilience amid an uneven operating environment. …
Repligen Corporation reported a robust first quarter 2026 with revenues of $194 million, up 15% year-over-year, and adjusted EPS growth of 23%. The company reiterated its full-year organic revenue growth guidance of 9%-13%, while increasing adjusted EPS guidance to $1.97-$2.05. Key strategic moves include launching a Transformation Office to enhanc…
NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies, will release its first quarter 2026 financial results on May 12, 2026, prior to market open. The company will also host a conference call to discuss the results and business update. NeurAxis focuses on the commercialization of its proprietary PENFS technology, I…
Relmada Therapeutics announced presentations of two abstracts related to NDV-01, their sustained-release gemcitabine-docetaxel formulation for non-muscle invasive bladder cancer (NMIBC), at the American Urology Association 2026 event. Phase 2 data in high-risk NMIBC patients showing 9-12 month efficacy results will be presented, alongside a Phase 3…
Arvinas, a biotechnology company specializing in targeted protein degradation therapies, announced it will release its first quarter 2026 financial results on May 12, 2026, accompanied by a corporate update webcast. The company continues advancing multiple clinical-stage investigational drugs, including FDA-approved VEPPANU developed with Pfizer fo…
EVgo Inc. announced strong first quarter 2026 financial results, achieving record revenues of $110 million, a 45% increase year-over-year. The company expanded its public fast charging stalls by 25% to 5,280 and grew network throughput by 10%, reinforcing its leadership in the U.S. EV charging market. Key strategic initiatives include scaling the n…
Ocular Therapeutix announced its first quarter 2026 financial results along with significant clinical progress in its AXPAXLI program for wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Key highlights include positive Phase 3 SOL-1 trial results demonstrating superiority over existing anti-VEGF treatment, initiation of the …
Eupraxia Pharmaceuticals reported encouraging EREFS (Endoscopic Reference Score) data from the ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data show that a higher number of esophageal wall injections (20 injections) resulted in significant improvement in inflammation and fibrosis scores, supporting …
